Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials

Publikation: Bidrag til tidsskriftReviewForskningpeer review


  1. Checkpoint inhibitors in pancreatic cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Checkpoint inhibitors in breast cancer - Current status

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. A systematic review of bevacizumab efficacy in breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Ilary Ruscito
  • Filippo Bellati
  • Isabelle Ray-Coquard
  • Mansoor Raza Mirza
  • Andreas du Bois
  • Maria Luisa Gasparri
  • Flavia Costanzi
  • Maria Paola De Marco
  • Marianna Nuti
  • Donatella Caserta
  • Sandro Pignata
  • Oliver Dorigo
  • Jalid Sehouli
  • Elena Ioana Braicu
Vis graf over relationer

BACKGROUND: The second decade of 2000s is witnessing a new ovarian cancer (OC) paradigm shift thanks to the results recently obtained by a new class of targeted agents: the Poly(ADP-ribose)polymerase (PARP)-Inhibitors (PARPi). Aim of this meta-analysis is to analyze available results obtained with PARPi, administered alone or in combination with chemo- and/or target-therapies in terms of efficacy and safety for the treatment of recurrent and primary advanced OC.

METHODS: On December 2019, all published phase II/III randomized clinical studies were systematically searched using the terms "[Parp-Inhibitor] AND [ovar*]". Twelve phase II/III randomized controlled trials were identified, with a total number of 5171 patients included.

RESULTS: Results demonstrated that PARPi account for a significant improvement of PFS in both recurrent and primary OC setting, independently from their administration schedule and independently from patients' BRCA mutational status. Moreover, patients harboring a Homologous Recombination Deficiency (HRD) positive testing primary or recurrent OC progress significantly later after PARPi administration/association. Results also reported that PARPi increase the occurrence of severe (G3-G4) anemia. Furthermore, severe fatigue occurred more frequently among patients subjected to PARPi combined with chemotherapy and to PARPi plus Bevacizumab. Finally, a significant increase in severe high blood pressure occurrence was observed when PARPi was added to antiangiogenetics, compared to PARPi alone but a significant decrease in G3-G4 hypertension occurrence was found in PARPi plus bevacizumab users compared to Bevacizumab alone.

CONCLUSIONS: PARPi are a valid option for the treatment of both primary and relapsed OC patients, with a relative low incidence of severe side effects.

TidsskriftCancer Treatment Reviews
Sider (fra-til)102040
StatusUdgivet - jul. 2020

Bibliografisk note

Copyright © 2020 Elsevier Ltd. All rights reserved.

ID: 60986936